Major adverse clinical events according to antithrombotic therapy at baseline discharge
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Stroke, n (%) | 2 (0.3) | 11 (1.7) | 22 (0.6) | 20 (0.6) | 8 (0.7) | 0.0453 |
| Any TE, n (%) | 9 (1.6) | 16 (2.4) | 40 (1.0) | 37 (1.2) | 14 (1.2) | 0.0530 |
| Haemorrhagic events, n (%) | 8 (1.4) | 15 (2.3) | 95 (2.4) | 74 (2.4) | 30 (2.7) | 0.5797 |
| Intracranial haemorrhage, n (%) | 1 (0.2) | 2 (0.3) | 12 (0.3) | 6 (0.2) | 3 (0.3) | 0.8932 |
| Acute coronary syndrome, n (%) | 6 (1.1) | 27 (4.1) | 49 (1.2) | 24 (0.8) | 42 (3.7) | <0.0001 |
| CV death, n (%) | 17 (2.9) | 47 (6.9) | 157 (3.9) | 64 (2.0) | 95 (8.2) | <0.0001 |
| All-cause death, n (%) | 30 (5.1) | 60 (8.8) | 196 (4.8) | 100 (3.2) | 115 (9.9) | <0.0001 |
| Any TE/ACS/CV death, n (%) | 31 (5.4) | 81 (12.1) | 240 (6.0) | 122 (3.9) | 144 (12.5) | <0.0001 |
| Any readmission, n (%) | 120 (21.4) | 176 (27.6) | 912 (23.4) | 723 (23.5) | 326 (29.7) | <0.0001 |
| Any AF readmission, n (%) | 48 (8.5) | 67 (10.4) | 405 (10.3) | 354 (11.5) | 135 (12.3) | 0.0915 |
| Any CV readmission, n (%) | 85 (15.2) | 151 (23.6) | 745 (19.1) | 561 (18.2) | 278 (25.2) | <0.0001 |
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Stroke, n (%) | 2 (0.3) | 11 (1.7) | 22 (0.6) | 20 (0.6) | 8 (0.7) | 0.0453 |
| Any TE, n (%) | 9 (1.6) | 16 (2.4) | 40 (1.0) | 37 (1.2) | 14 (1.2) | 0.0530 |
| Haemorrhagic events, n (%) | 8 (1.4) | 15 (2.3) | 95 (2.4) | 74 (2.4) | 30 (2.7) | 0.5797 |
| Intracranial haemorrhage, n (%) | 1 (0.2) | 2 (0.3) | 12 (0.3) | 6 (0.2) | 3 (0.3) | 0.8932 |
| Acute coronary syndrome, n (%) | 6 (1.1) | 27 (4.1) | 49 (1.2) | 24 (0.8) | 42 (3.7) | <0.0001 |
| CV death, n (%) | 17 (2.9) | 47 (6.9) | 157 (3.9) | 64 (2.0) | 95 (8.2) | <0.0001 |
| All-cause death, n (%) | 30 (5.1) | 60 (8.8) | 196 (4.8) | 100 (3.2) | 115 (9.9) | <0.0001 |
| Any TE/ACS/CV death, n (%) | 31 (5.4) | 81 (12.1) | 240 (6.0) | 122 (3.9) | 144 (12.5) | <0.0001 |
| Any readmission, n (%) | 120 (21.4) | 176 (27.6) | 912 (23.4) | 723 (23.5) | 326 (29.7) | <0.0001 |
| Any AF readmission, n (%) | 48 (8.5) | 67 (10.4) | 405 (10.3) | 354 (11.5) | 135 (12.3) | 0.0915 |
| Any CV readmission, n (%) | 85 (15.2) | 151 (23.6) | 745 (19.1) | 561 (18.2) | 278 (25.2) | <0.0001 |
ACS, acute coronary syndrome; AF, atrial fibrillation; CV, cardiovascular; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation; TE, thromboembolism; VKA, vitamin K antagonist.
Major adverse clinical events according to antithrombotic therapy at baseline discharge
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Stroke, n (%) | 2 (0.3) | 11 (1.7) | 22 (0.6) | 20 (0.6) | 8 (0.7) | 0.0453 |
| Any TE, n (%) | 9 (1.6) | 16 (2.4) | 40 (1.0) | 37 (1.2) | 14 (1.2) | 0.0530 |
| Haemorrhagic events, n (%) | 8 (1.4) | 15 (2.3) | 95 (2.4) | 74 (2.4) | 30 (2.7) | 0.5797 |
| Intracranial haemorrhage, n (%) | 1 (0.2) | 2 (0.3) | 12 (0.3) | 6 (0.2) | 3 (0.3) | 0.8932 |
| Acute coronary syndrome, n (%) | 6 (1.1) | 27 (4.1) | 49 (1.2) | 24 (0.8) | 42 (3.7) | <0.0001 |
| CV death, n (%) | 17 (2.9) | 47 (6.9) | 157 (3.9) | 64 (2.0) | 95 (8.2) | <0.0001 |
| All-cause death, n (%) | 30 (5.1) | 60 (8.8) | 196 (4.8) | 100 (3.2) | 115 (9.9) | <0.0001 |
| Any TE/ACS/CV death, n (%) | 31 (5.4) | 81 (12.1) | 240 (6.0) | 122 (3.9) | 144 (12.5) | <0.0001 |
| Any readmission, n (%) | 120 (21.4) | 176 (27.6) | 912 (23.4) | 723 (23.5) | 326 (29.7) | <0.0001 |
| Any AF readmission, n (%) | 48 (8.5) | 67 (10.4) | 405 (10.3) | 354 (11.5) | 135 (12.3) | 0.0915 |
| Any CV readmission, n (%) | 85 (15.2) | 151 (23.6) | 745 (19.1) | 561 (18.2) | 278 (25.2) | <0.0001 |
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Stroke, n (%) | 2 (0.3) | 11 (1.7) | 22 (0.6) | 20 (0.6) | 8 (0.7) | 0.0453 |
| Any TE, n (%) | 9 (1.6) | 16 (2.4) | 40 (1.0) | 37 (1.2) | 14 (1.2) | 0.0530 |
| Haemorrhagic events, n (%) | 8 (1.4) | 15 (2.3) | 95 (2.4) | 74 (2.4) | 30 (2.7) | 0.5797 |
| Intracranial haemorrhage, n (%) | 1 (0.2) | 2 (0.3) | 12 (0.3) | 6 (0.2) | 3 (0.3) | 0.8932 |
| Acute coronary syndrome, n (%) | 6 (1.1) | 27 (4.1) | 49 (1.2) | 24 (0.8) | 42 (3.7) | <0.0001 |
| CV death, n (%) | 17 (2.9) | 47 (6.9) | 157 (3.9) | 64 (2.0) | 95 (8.2) | <0.0001 |
| All-cause death, n (%) | 30 (5.1) | 60 (8.8) | 196 (4.8) | 100 (3.2) | 115 (9.9) | <0.0001 |
| Any TE/ACS/CV death, n (%) | 31 (5.4) | 81 (12.1) | 240 (6.0) | 122 (3.9) | 144 (12.5) | <0.0001 |
| Any readmission, n (%) | 120 (21.4) | 176 (27.6) | 912 (23.4) | 723 (23.5) | 326 (29.7) | <0.0001 |
| Any AF readmission, n (%) | 48 (8.5) | 67 (10.4) | 405 (10.3) | 354 (11.5) | 135 (12.3) | 0.0915 |
| Any CV readmission, n (%) | 85 (15.2) | 151 (23.6) | 745 (19.1) | 561 (18.2) | 278 (25.2) | <0.0001 |
ACS, acute coronary syndrome; AF, atrial fibrillation; CV, cardiovascular; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation; TE, thromboembolism; VKA, vitamin K antagonist.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
